Hexarelin 5 mg: The Potent Growth Hormone Releaser with Verified Purity
Dragon Pharma presents Hexarelin 5 mg, a premium growth hormone-releasing peptide renowned for its exceptional potency and reliable performance. As one of the most powerful synthetic hexapeptides in the GHRP class, Hexarelin stimulates profound pulses of endogenous growth hormone, making it a valuable subject for research in muscle growth, fat loss, and recovery enhancement. What sets Dragon Pharma’s Hexarelin apart is its verified purity—third-party laboratory testing confirms an actual content of 5.34 mg per vial, exceeding the labeled potency and providing researchers with confidence in product quality and consistency for their studies.
DRUG DESCRIPTION
Dragon Pharma’s Hexarelin is supplied as a sterile, lyophilized powder in a 5 mg / 2 mL vial, with independent laboratory verification showing 5.34 mg actual content (test date: 2025-09-12). This synthetic hexapeptide (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2) functions as a potent growth hormone secretagogue with a unique pharmacological profile. Hexarelin exhibits high binding affinity to the ghrelin receptor (GHSR-1a), triggering powerful pituitary GH release. Its distinctive characteristic is its ability to maintain efficacy with repeated administration, showing less desensitization than other GHRPs. Beyond GH release, Hexarelin has demonstrated cardioprotective properties in research settings and influences various metabolic pathways, making it a multifaceted compound for comprehensive performance and recovery studies.
HEXARELIN PROFILE
Drug Class: Growth Hormone Secretagogue
Main Active Substance: Hexarelin
Concentration: 5 mg/vial
Presentation: 2 mL Vial
Elimination Half-Life: ~1-2 hours
Recommended Dosage: 50-150 mcg, 1-2 times daily
Anabolic Ratio: N/A
Androgenic Ratio: N/A
Acne: None
Hepatotoxicity: None
Aromatization: No
Manufacturer: Dragon Pharma
LAB TEST REPORT
Dragon Pharma is committed to transparency and quality assurance. Independent third-party laboratory analysis conducted on September 12, 2025, confirms that our Hexarelin 5 mg vials contain 5.34 mg of active substance, representing a 106.8% potency verification. This exceeds the labeled amount and demonstrates Dragon Pharma’s commitment to providing researchers with high-quality, accurately dosed compounds. The laboratory testing utilized advanced HPLC (High-Performance Liquid Chromatography) methodology to verify both purity and concentration, ensuring researchers can trust the consistency and reliability of their experimental results when using Dragon Pharma Hexarelin.
HOW TO USE HEXARELIN
For research purposes, Hexarelin 5 mg is reconstituted with bacteriostatic water. Research protocols typically involve 1-2 administrations daily due to its relatively short half-life (approximately 1-2 hours). The most effective timing is on an empty stomach, as food intake can significantly blunt the GH response. Many researchers administer upon waking and pre-workout to maximize anabolic signaling during key physiological windows. Hexarelin is frequently researched in sophisticated peptide stacks. It combines powerfully with CJC-1295 DAC for sustained 24-hour GH elevation. For advanced body recomposition, it can be stacked with Trenbolone 100 to create a powerful anabolic and metabolic environment. To manage potential prolactin increases, researchers may include Caber (Cabergoline) in their protocol. For enhanced recovery alongside GH benefits, it can be combined with BPC-157 for comprehensive tissue repair. During cutting phases, it can be researched with T3 (Cytomel) to optimize metabolic rate while preserving muscle tissue.
POSSIBLE SIDE EFFECTS
Hexarelin is generally well-tolerated in research settings, though its high potency can produce more pronounced effects than other GHRPs. Common transient effects include mild flushing, tingling sensations, or temporary lethargy following administration. Unlike GHRP-6, Hexarelin typically does not cause significant hunger stimulation. A notable consideration with Hexarelin is its potential to moderately increase prolactin and cortisol levels in some research subjects, though this effect is typically dose-dependent and manageable. Some researchers report acute GH release can cause temporary joint stiffness or fluid retention as IGF-1 levels rise. The verified purity of Dragon Pharma’s formulation minimizes concerns about impurities or underdosing that could affect research outcomes.
CONCLUSION
Dragon Pharma’s Hexarelin 5 mg represents the gold standard in growth hormone-releasing peptide research, combining exceptional potency with verified quality through independent laboratory testing. Its ability to produce robust, reliable GH pulses with maintained efficacy over time makes it a superior choice for researchers seeking maximum anabolic and metabolic benefits. The third-party verification of 5.34 mg actual content provides unprecedented confidence in dosing accuracy, ensuring research protocols yield consistent and reproducible results. For bodybuilders and performance researchers, Hexarelin offers a powerful tool for exploring the limits of natural growth hormone optimization, with potential applications in muscle growth, fat loss, recovery enhancement, and overall metabolic health.
HEXARELIN FAQ
Hexarelin is considered the most potent of the three major GHRPs in stimulating GH release. Research suggests it may produce significantly higher GH pulses than GHRP-6 or GHRP-2 at equivalent doses, though it may have different effects on cortisol and prolactin that require consideration in research design.
Third-party verification ensures accurate dosing and purity, which are critical for reproducible research results. Underdosed or impure compounds can lead to inconsistent data and unreliable conclusions. Dragon Pharma’s commitment to independent testing provides researchers with confidence in their experimental materials.
Hexarelin shows less tachyphylaxis (desensitization) than other GHRPs with repeated administration. However, many researchers still implement cycling protocols (e.g., 5 days on/2 days off or 4-6 week cycles) to maintain optimal pituitary responsiveness during long-term studies.
The actual 5.34 mg content represents a 6.8% overfill, meaning researchers are receiving slightly more active peptide than labeled. This provides a buffer against potential minor losses during reconstitution and administration while ensuring the intended dose is delivered. For scientific context on GH secretagogues, see: National Library of Medicine – GH Secretagogues.
Yes, unlike GHRP-6 which significantly increases hunger, Hexarelin typically does not cause notable appetite changes. This makes it particularly suitable for cutting phases or research protocols where controlled calorie intake is essential for the study objectives.